European Union: Recent Important Decisions On Regulatory Requirements For Parallel Trade In The EU

Last Updated: July 30 2019
Article by Ian Dodds-Smith, Jacqueline Mulryne and Silvia Valverde

Ordinarily, medicinal products can only be placed on the market in the EU if they have a valid marketing authorisation in the relevant Member State. However, within the EEA (28 EU Member States, plus Iceland, Liechtenstein and Norway), the principle of free movement of goods applies, meaning that, subject to exceptions such as the imposition of proportionate restrictions to protect public health, Member States cannot erect barriers to free movement of goods once they are lawfully on the EEA market. IP rights are another relevant factor, but such rights are not covered in this article. Therefore, once a product has lawfully been placed on the market in the EU, it is possible for third parties to move that product between Member States, subject to certain requirements. This is known as parallel trade.

Requirements for Parallel Trade

The Court of Justice of the European Union (CJEU) has stated that the requirement to have a marketing authorisation to place medicinal products on the market is subject to exceptions, and national competent authorities would be obstructing parallel trade without proper and proportionate justification, if they required parallel traders of certain products to satisfy the same requirements as those necessary for a full marketing authorisation. Therefore, a simplified approval procedure applies where an authorised product that is lawfully on the market in one Member State is imported into another Member State, provided the imported product is identical or sufficiently similar to an authorised Reference Product in the Member State of destination.

The reason for allowing this form of simplified procedure is that if the products concerned are essentially the same, the information required to ensure public health is protected is already available to the competent authorities of the Member State of destination by virtue of the first marketing authorisation for the Reference Product in that Member State. There is, therefore, no need to repeat this process for the imported product. The theory that is applied is that, in these circumstances, the parallel traded product enters the country of destination under the "umbrella" of the existing marketing authorisation for the Reference Product. The question that has given rise to much case law in the European Court is in what circumstances can the import be treated as sufficiently similar so full assessment is not needed in the country of import?

Early case law of the CJEU on this issue concerned identical products placed on the market by the same company or companies within the same corporate group. The fact that the products had a "common origin" created an assumption of conformity in respect of the two products and this was viewed as necessary to allow the imported product to rely upon the authorisation of the Reference Product and justify import without further particulars being required.

In Smith & Nephew, however, the imported product and the Reference Product were manufactured by different legal entities, albeit under a licence granted by the same licensor. This was considered by the CJEU to be akin to having a common origin, and so the products were deemed "sufficiently similar" for the purposes of parallel importation, provided they had the same formulation and the same therapeutic effect.

In Rhône-Poulenc, the CJEU clarified the requirement for "same formulation", and determined that products will be considered as "sufficiently similar" if their active ingredients and therapeutic effects are the same, even if the excipients are different and, therefore, the formulations of each cannot be said to be the same.

As such, a parallel import licence can normally be granted if it can be shown that the imported product and the domestic Reference Product have the same formulation (although they may have different excipients) and the same active substance, and have the same therapeutic effect.

Reference and Generic Products

In 2004, the requirement of "common origin" of the imported product and the Reference Product was surprisingly and controversially removed or at least downgraded as a requirement in Kohlpharma, when the CJEU stated that failure to establish a common origin of the products does not necessarily preclude the grant of a parallel import licence. The CJEU stated that the imported and Reference Product in the country of destination do not have to be identical, but could be "substantially identical/essentially similar", as long as there are no safety concerns. "Essential similarity" was a prerequisite for approval of generics before legislative changes in 2004. Now the definition of generic medicinal product in Article 10 of Directive 2001/83/EC contains the same concept.

This decision creates a tension with the regulatory framework for grant of copy (generic) marketing authorisations because it implied that, for instance, a generic product could be placed on the market in a single country, and the generic authorisation holder would not need to obtain an authorisation in any other Member State, but could simply parallel import the product into those other markets, by showing it was "substantially identical" to the Reference Product on the market in those countries. It would, of course, be able to demonstrate such similarity as a result of being approved as a generic of that Reference Product. This decision also conflicted with case law on parallel trade in other similarly regulated product fields, such as plant protection products, where case law indicated that the criterion of common origin remained important to justify a simplified procedure.

We are aware that competent authorities across the EU are interpreting this uncertainty in different ways, and that there have been a number of questions raised about the full implications of the Kohlpharma decision.

Case C-387/18, Delfarma

This issue has resurfaced in the CJEU in a recent case from Poland: Case C-387/18, Delfarma. This case related to national legislation in Poland that stated that it was a requirement for obtaining a parallel import licence to demonstrate that the imported and the domestic Reference Product were either both approved as Reference Products or both approved as generic medicinal products. This requirement would, for instance, avoid a generic medicinal product being imported into Poland where there was no existing generic medicinal product approved, perhaps because the protection period in Poland for the Reference Product had not yet expired.

In this case, Delfarma, a parallel trader, was denied a parallel trade licence to import Azithromycin 500mg into Poland from the UK. This was due to the fact that the product in Poland was granted on the basis of a full marketing authorisation application, while the product in the UK was authorised as a generic product, and therefore, the requirements of Polish law were not met.

Delfarma challenged this decision on the basis that the products were substantially the same despite being authorised under different legal bases and on the basis of different documentation, and argued that the additional requirement under Polish law was a restriction to the free movement goods. Indeed, it was shown in this case that the Polish authority did not examine the actual products, or their therapeutic effects, despite having availability to the relevant data from the UK competent authority, and having the ability to request additional information from this competent authority if considered necessary. The refusal of the parallel import licence was purely due to the fact that one product was a Reference Product while the other was a generic product.

Findings of the CJEU

The CJEU re-affirmed its interpretation, set out above, that the Member State of import must ensure that the imported medicine and the domestic Reference product, "without being totally identical", have been manufactured with the same formulation and using the same active substance, and have the same therapeutic effects; and that the medicine to be imported does not raise concerns from a quality, efficacy and safety point of view. If the Member State of import confirms that these criteria are satisfied, the imported product should be granted a parallel import licence on the basis of the existing national marketing authorisation. The CJEU stated that it was not relevant that the import and the domestic product were respectively a generic product and a Reference Product.

While the Polish government argued that without the national restriction in question, the parallel import procedure could be used to circumvent the marketing authorisation procedure, this was not accepted by the CJEU. The court stated that such a restriction was not necessary to protect the EU marketing authorisation procedure as both procedures were capable of establishing that the products in question met the criteria of safety, efficacy and quality. The court noted that Directive 2001/83/EC "does not apply" to parallel imported products, as the imported product must comply with the criteria set out above, and the competent authority of import is responsible for verifying that all of those requirements are complied with before issuing a parallel import licence.

Further, the court said that once a "plausible case" of similarity has been advanced by the parallel trader, the burden is upon the regulatory authority to check whether there are any differences between the products, if necessary by obtaining information from the competent authority in the country of export. The Polish government argued that a product might be a valid generic of the Reference Product in the country of export, but that did not mean it was a valid generic of the Reference Product in Poland (which we believe is correct when dealing with national authorisations approved outside a decentralised and mutual recognition procedure). It seemingly argued that the parallel trade procedures were premised on it being unnecessary to conduct detailed reviews, but the court clarified that the administrative burden, in terms of time and cost, could not be used to justify restrictions on free movement unless the amounts involved were unreasonably high.

It follows that the CJEU has confirmed that a parallel trader can import a generic product into a Member State in which that product does not have a marketing authorisation but can rely upon the existing authorisation for the Reference Product in the country of import. The company can, therefore, treat the generic product as having been placed on the market in the country of import, despite the lack of an equivalent generic authorisation in that country.

The view of the court that this does not have the potential to undermine the existing regulatory framework appears simplistic and the decision could have wide-reaching implications for parallel imports across the EU. It remains to be seen how national competent authorities will apply this decision in practice. The conflicting case law concerning the relevance of the "common origin" of both the Reference Product and the imported product is not discussed in the decision and, therefore, has not been resolved, but the decision certainly implies that "common origin" is no longer a critical consideration.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions